Materials and methods for inhibiting Wip1

US7456268B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Dmitry Bulavin · Singapore, SG
• Ettore Appella · Bethesda, US
• Albert J. Fornace, Jr. · Bethesda, US
• Anne Kallioniemi · Tampere, FI

Key dates

• Filing date: Oct 8, 2007
• Grant date: Nov 25, 2008
• Expiry date: Oct 8, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, comprising administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor; a method of screening an oligonucleotide or morpholino oligomer for the ability to inhibit the expression of Wip1; a method of determining the efficacy with which a test oligonucleotide or morpholino oligomer inhibits Wip1 expression; a method of screening a compound for Wip1-inhibiting activity; and a method of determining the efficacy with which a test compound inhibits Wip1.